SummitTX Capital L.P. Has $756,000 Stock Holdings in Perrigo Company plc $PRGO

SummitTX Capital L.P. decreased its holdings in Perrigo Company plc (NYSE:PRGO) by 48.0% during the 1st quarter, according to the company in its most recent filing with the SEC. The fund owned 70,375 shares of the company’s stock after selling 64,883 shares during the period. SummitTX Capital L.P. owned approximately 0.05% of Perrigo worth $756,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Amundi grew its position in Perrigo by 11.7% in the first quarter. Amundi now owns 5,292 shares of the company’s stock valued at $148,000 after acquiring an additional 556 shares during the last quarter. Kestra Investment Management LLC lifted its holdings in shares of Perrigo by 57.1% in the second quarter. Kestra Investment Management LLC now owns 1,766 shares of the company’s stock worth $47,000 after acquiring an additional 642 shares during the last quarter. Geneos Wealth Management Inc. boosted its stake in shares of Perrigo by 439.1% in the 1st quarter. Geneos Wealth Management Inc. now owns 965 shares of the company’s stock valued at $27,000 after purchasing an additional 786 shares in the last quarter. EverSource Wealth Advisors LLC boosted its stake in shares of Perrigo by 116.0% in the 4th quarter. EverSource Wealth Advisors LLC now owns 1,888 shares of the company’s stock valued at $26,000 after purchasing an additional 1,014 shares in the last quarter. Finally, Covestor Ltd grew its holdings in shares of Perrigo by 14.4% during the 4th quarter. Covestor Ltd now owns 8,991 shares of the company’s stock valued at $125,000 after purchasing an additional 1,129 shares during the last quarter. Institutional investors and hedge funds own 95.91% of the company’s stock.

Perrigo Stock Performance

Shares of PRGO stock opened at $10.36 on Friday. The firm has a market capitalization of $1.43 billion, a price-to-earnings ratio of -0.79, a PEG ratio of 1.24 and a beta of 0.51. The company has a current ratio of 2.72, a quick ratio of 1.59 and a debt-to-equity ratio of 1.45. The business’s 50-day moving average price is $10.55 and its 200-day moving average price is $11.65. Perrigo Company plc has a 12 month low of $9.23 and a 12 month high of $27.33.

Perrigo (NYSE:PRGO) last released its quarterly earnings data on Wednesday, May 6th. The company reported $0.43 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.39 by $0.04. The company had revenue of $841.80 million during the quarter, compared to the consensus estimate of $1.04 billion. Perrigo had a positive return on equity of 9.96% and a negative net margin of 43.50%.The firm’s revenue was down 7.2% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.60 earnings per share. Perrigo has set its FY 2026 guidance at 2.250-2.550 EPS. Equities research analysts forecast that Perrigo Company plc will post 2.11 EPS for the current year.

Perrigo Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 15th. Shareholders of record on Friday, August 28th will be given a $0.29 dividend. This represents a $1.16 annualized dividend and a yield of 11.2%. The ex-dividend date is Friday, August 28th. Perrigo’s dividend payout ratio is -8.85%.

Analysts Set New Price Targets

PRGO has been the subject of several research reports. Zacks Research raised shares of Perrigo from a “strong sell” rating to a “hold” rating in a research note on Monday, April 27th. Weiss Ratings raised shares of Perrigo from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, July 21st. One investment analyst has rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $19.33.

Perrigo Profile

Perrigo Company plc is a global healthcare supplier specializing in over-the-counter (OTC) and self-care products, as well as generic prescription pharmaceuticals and active pharmaceutical ingredients. The company develops, manufactures and distributes a broad array of consumer health products, including analgesics, vitamins and supplements, digestive health remedies, topical treatments, and infant formulas. Perrigo’s focus on private-label solutions has made it a leading partner for retailers and pharmacy chains seeking high-quality, value-oriented alternatives to branded medications and health supplements.

Organized across three principal business segments—Consumer Healthcare, Prescription Pharmaceuticals and Active Pharmaceutical Ingredients—Perrigo’s operations span research and development, manufacturing, quality assurance and global distribution.